Sai Life Sciences

As of 2026-11-06, SAILIFE exhibits a strong bullish technical structure across daily, weekly, and monthly timeframes. The stock closed at ₹1768.00, up +10.9% on the day, trading near its available high with a range position of +95.5% over the past year. Trend indicators confirm this strength: the ADX is 26.14 on the daily chart (established trend) and 74.6 on the monthly chart (strong trend), while price remains above all key moving averages and the Supertrend indicator.

Participation was extreme on 2026-11-06, with volume surging 27.49 times the average alongside a +12.5% intraday range. This follows a downward gap on 2026-11-04, which appears to have been absorbed as buyers stepped in aggressively. Risk metrics show an annualized volatility of +38.6% and a maximum historical drawdown of -18.6%. Current support levels are identified at ₹1663.20 (-5.93%) and ₹1631.10 (-7.74%).

The setup is confirmed by sustained price action above short-term averages. A weakening of this setup would be signaled by a close below the 20-day moving average or a break below the ₹1663.20 support level, which could invalidate the immediate bullish momentum.

Sai Life Sciences reported unaudited financial results for the half-year ended September 30, 2026, on November 5, 2026. The company recorded a Profit Before Tax of ₹4,561.73 million for the first half and ₹1,283.08 million for the second quarter. Concurrently, the Board appointed three senior management personnel effective November 5, 2026: Mr. Sidhartha Das (Senior Vice President & Head - Human Resources), Mr. Vijay Kumar Suthari (Vice President - Head Quality & Regulatory Affairs), and Mr. Sriram Gopalakrishnan (Senior Vice President - Corporate Communications). The company also allotted 108,005 fully paid-up equity shares under ESOP 2008 and MESOP 2018, increasing its issued share capital from ₹21,24,72,716 to ₹21,25,80,721. Deloitte Haskins & Sells LLP issued unmodified limited-review conclusions on these results. On November 6, 2026, the company uploaded audio recordings of the earnings call to its website and informed the NSE and BSE of the publication. The stock price was observed at ₹1,768.00 on November 6, 2026, compared to a previous close of ₹1,599.00.

Sai Life Sciences Limited reported unaudited financial results for the half-year ended September 30, 2026, on November 5, 2026. The company recorded a Profit Before Tax of ₹4,561.73 million for the first half and ₹1,283.08 million for the second quarter. Deloitte Haskins & Sells LLP issued unmodified limited-review conclusions on these results. Concurrently, the Board appointed three senior management personnel effective November 5, 2026: Sidhartha Das (Head - Human Resources), Vijay Kumar Suthari (Head Quality & Regulatory Affairs), and Sriram Gopalakrishnan (Corporate Communications). Additionally, the company allotted 108,005 fully paid-up equity shares upon the exercise of options under ESOP 2008 and MESOP 2018, increasing its issued share capital from ₹21,24,72,716 to ₹21,25,80,721. An earnings conference call was held on November 6, 2026, with recordings made available to investors.

Sai Life Sciences demonstrates a robust expansion in profitability and cash generation, though it faces near-term margin pressure from rising costs. For the full year ended March 2026, sales grew 4% year-on-year to ₹2,192 crore, while net profit surged 105% to ₹349 crore. This earnings acceleration is supported by strong operating leverage, with operating profit rising to ₹634 crore and ROCE improving significantly to 20%. Cash flow quality remains high, with CFO/EBITDA at 86% and total cash from operations increasing to ₹509 crore.

However, recent quarterly trends indicate tightening margins. In Q2 FY2026-27 (ended September 2026), revenue rose sequentially to ₹659 crore, but expenses increased faster, reaching ₹531 crore. Finance costs also ticked up to ₹10.9 crore. Despite this, net profit remained resilient at ₹98.3 crore, yielding an EPS of ₹4.63. The balance sheet shows active capital deployment, with Fixed Assets growing to ₹1,815 crore and CWIP rising sharply to ₹270 crore as of March 2026. Borrowings have been reduced steadily from ₹928 crore in March 2024 to ₹288 crore in March 2026, indicating deleveraging alongside expansion.

The most critical checkpoint for the next period is whether the company can stabilize expense growth relative to revenue, particularly given the sequential rise in finance costs and other expenses in Q2 FY2026-27.

Sai Life Sciences demonstrates strong technical momentum across multiple timeframes as of 6 November 2026, with the stock trading at ₹1768.00 and a market capitalization of approximately ₹33,866 crore. The daily Supertrend indicator remains bullish, supported by a Plus DI of 45.7 against a Minus DI of 11.08, indicating dominant buying pressure. This strength is corroborated by the monthly timeframe, where the ADX stands at 74.6, signaling a robust trend. Over the past year, the stock has delivered a return of +91.7%, contributing to a year-to-date gain of +96.4% and an all-time high return of +133.2% since the start of the tracked period. While the stock faces resistance near its recent high of ₹1814.90, support levels are identified at ₹1663.20 (5.93% below) and ₹1631.10 (7.74% below). The broader Indian pharmaceutical sector also shows resilience, with the sectoral index rising 27% year-to-date in 2026, driven by domestic demand and margin improvements.